- Open
- 551.00
- High
- 586.64
- Low
- 550.00
- Close
- 572.00
- Change
- +22.00 (4.00%)
- Volume
- 141,472
⌘K
| 8 Apr 2026 | 17:18:41 | Grant of Awards |
| 1 Apr 2026 | 07:00:03 | Total Voting Rights |
| 30 Mar 2026 | 15:30:31 | 2026 Annual General Meeting notification |
| 26 Mar 2026 | 07:00:06 | Preliminary results for the year ended 31 Dec 2025 |
| 30 Mar 2026 | Annual financial and audit reports | |
| 28 Apr 2025 | Annual financial and audit reports | |
| 30 Apr 2024 | Annual Report and accounts 31-Dec-2023 |
Oxford BioMedica is a company that specializes in gene and cell therapy, and is a leader in the research, development, and bioprocessing of lentiviral and cell therapy.
| 8 Apr 2026 | 17:18:41 | Grant of Awards |
| 1 Apr 2026 | 07:00:03 | Total Voting Rights |
| 30 Mar 2026 | 15:30:31 | 2026 Annual General Meeting notification |
| 26 Mar 2026 | 07:00:06 | Preliminary results for the year ended 31 Dec 2025 |
| 30 Mar 2026 | Annual financial and audit reports | |
| 28 Apr 2025 | Annual financial and audit reports | |
| 30 Apr 2024 | Annual Report and accounts 31-Dec-2023 |
Oxford BioMedica is a company that specializes in gene and cell therapy, and is a leader in the research, development, and bioprocessing of lentiviral and cell therapy.
| 18 Mar 2026 |
| 07:00:12 |
| Licensing agreement with VVMF |
| 20 Mar 2026 |
| Week Ahead: Kingfisher, Next, Fevertree, Ceres Power |
| 24 Feb 2026 | Oxford Biomedica trading update ignored as bid deadline looms |
| 18 Mar 2026 |
| 07:00:12 |
| Licensing agreement with VVMF |
| 20 Mar 2026 |
| Week Ahead: Kingfisher, Next, Fevertree, Ceres Power |
| 24 Feb 2026 | Oxford Biomedica trading update ignored as bid deadline looms |